

73. (New) The anticodon oligomer of Claim 71, wherein said anticodon oligomer is an antisense oligonucleotide complementary to a splice donor site of SEQ ID NO:22.

74. (New) The anticodon oligomer of Claim 70, wherein said anticodon oligomer is 10 to 40 bases in length and is complementary to a 5'-untranslated region of SEQ ID NO:19.

75. (New) A composition comprising the anticodon oligomer of Claims 53, 70, 71, 72, 73 or 74; and a pharmaceutically acceptable carrier.

76. (New) The anticodon oligomer of Claim 53, wherein said anticodon oligomer contains at least one phosphorothioate-modified nucleotide.

77. (New) A composition comprising the anticodon oligomer of Claim 76; and a pharmaceutically acceptable carrier.

78. (New) The anticodon oligomer of Claim 76, wherein said anticodon oligomer is a phosphodiester/phosphorothioate chimera.

79. (New) The anticodon oligomer of Claim 76 wherein the oligonucleotide comprises at least 2 to 3 phosphorothioate linkages.

80. (New) A composition comprising the anticodon oligomer of Claim 78 or 79; and a pharmaceutically acceptable carrier.

81. (New) The anticodon oligomer of Claim 53, wherein said anticodon oligomer contains at least one phosphoramidate-modified nucleotide.

82. (New) The anticodon oligomer of Claim 70, 71, 72, 73 or 74, wherein said anticodon oligomer contains at least one phosphorothioate-modified nucleotide.

83. (New) A composition comprising the anticodon oligomer of Claim 82; and a pharmaceutically acceptable carrier.

84. (New) The anticodon oligomer of Claim 82, wherein said anticodon oligomer is a phosphodiester/phosphorothioate chimera.